Lactobacillus Paracasei

If you take a probiotic and want to know whether anything got through, this test answers the first half of that question. A stool PCR result tells you whether Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) DNA is present in your stool and roughly how much.

What it doesn't do is diagnose anything. There are no validated reference ranges for this organism, and in people who eat no fermented foods and take no supplements, baseline levels are often very low or undetectable. That is normal, not a deficiency.

What the Test Actually Detects

PCR is a lab method that copies selected pieces of DNA until they can be counted. For this organism, the assay targets DNA sequences unique enough to separate it from close relatives in the lactic acid bacteria family.

DNA is not the same as a living bacterium. Total counts measured by PCR routinely run higher than counts of viable, colony-forming bacteria, because dead bacterial DNA is still detected. A high number means genetic material passed through, not necessarily that a thriving colony has set up residence.

That distinction matters more here than for most gut bacteria. This species is largely a passenger, not a resident.

Passage, Not Permanent Colonization

The clearest human data come from controlled feeding studies. In healthy adults given the CNCM I-1572 strain, marketed as L. casei DG, culture followed by strain-specific PCR recovered viable bacteria from every participant. The highest viable stool counts ranged from roughly 3.6 to 6.7 on a log scale, a thousandfold spread between the lowest and highest responders.

The organism clears, but how fast depends on the strain and on you. In adult studies, the CNCM I-1572 and LPC-S01 strains stayed detectable for about five days after the last dose, disappearing after roughly seven bowel movements. In children given CNCM I-1572, the strain persisted up to about three days after stopping, while reviews of probiotic passage describe some strains recoverable anywhere from one to four weeks after the last dose, with a subset of people holding on longer. Transit time and your existing gut community both shift the timeline. Stop taking the supplement and the signal usually goes with it, but there is no single number of days that applies to everyone.

So a low or undetectable result on a baseline panel, in someone taking no probiotic, does not mean anything is wrong. Across unsupplemented cohorts, this species is often near zero or under a tenth of a percent of total gut bacteria. It is not a species your gut is supposed to be full of.

What Supplementation Has Been Shown to Do

The clinical trials below tested named products or strains. They do not show that a higher baseline stool number is better.

Stool consistency has the most human data, and the results are genuinely mixed. In a randomized trial in U.S. adults with a history of hard or lumpy stools, fermented milk containing the Shirota strain cut the odds of a hard stool to about a third of control. A separate placebo-controlled trial using a device that measures stool firmness found higher water content and softer consistency in the subgroup whose stools were physically hard at baseline, without a clear effect across everyone enrolled. Pooled evidence is less encouraging: a meta-analysis of probiotic trials in functional constipation found no significant improvement in stool frequency or consistency with the Shirota strain, and the 2025 British Dietetic Association constipation guideline concluded, on very low-quality evidence, that it does not improve overall constipation symptoms. The benefit, if it exists, looks confined to particular strains and particular subgroups.

In people with depression and constipation, nine weeks of the Shirota strain improved bowel evacuation symptoms compared with placebo, and that trial also reported lower blood interleukin-6, an inflammatory signal. Don't read that as an established anti-inflammatory effect. A 2026 review pooling probiotic trials in depression found improvement in depressive symptoms without a significant change in interleukin-6 or TNF-alpha, and a single-arm Shirota trial in depression found no change in inflammation markers at all.

Irritable Bowel Syndrome

Here the picture is more restrained than most probiotic marketing. A pilot randomized trial of the CNCM I-1572 strain in irritable bowel syndrome shifted gut bacteria, raised the short-chain fatty acids acetate and butyrate, and lowered fecal interleukin-15. Interleukin-15 is an inflammatory signal. Symptoms did not significantly improve overall.

A later post-hoc analysis suggested one reason averages can look flat. In non-constipated irritable bowel syndrome, responders had a distinctive starting microbiome, with more Collinsella aerofaciens and related bacteria. The studied product provided at least 24 billion colony-forming units per capsule and was taken twice daily. Whether this probiotic helps your gut symptoms may depend on which bacteria you already carry, not on how much of this one you carry.

That is the strongest practical argument for testing alongside a broader stool panel rather than testing this species alone.

Blood Pressure and Metabolic Signals

In a cross-sectional study of 6,953 adults, greater abundance of this species went with lower average blood pressure and lower dietary sodium. Cross-sectional means measured at one point in time. It does not prove that the bacteria lowered anyone's pressure. People who eat more fermented food and less salt differ in many ways.

The prospective follow-up is sobering. A 20-year cohort of 3,311 people looking at gut bacteria and future high blood pressure found no strong link once the usual differences between people were accounted for. Treat the cross-sectional finding as a lead, not a result.

Intervention trials in metabolic conditions are small. A randomized trial in 58 people with metabolic syndrome risk factors, using this species combined with a Bifidobacterium, reported lower LDL cholesterol alongside lower systolic pressure. Separate small trials in people with high cholesterol also reported LDL reductions. These are promising but too small to settle the question, and none used a stool PCR level to decide who should be treated.

Why Higher Is Not Automatically Better

For this marker, there is no good-number, bad-number rule. Its level in stool mostly reports on recent intake and recent transit, not on the health of your gut lining.

Reading a single value as if higher were healthier reverses the causal arrow. Supplementation raises the number reliably; the number rising does not tell you the underlying biology improved.

Why a Single Reading Can Fool You

Day-to-day variation in gut bacteria is large, and this is the one thing to know before you act on one result. In daily sampling of 713 stool specimens from 20 people, 78% of bacterial genera varied more within one person over time than between different people, with swings up to a hundredfold. A separate week-long sampling study also found large within-person variation for many gut genera.

Several specific things distort a reading:

• Recent intake: a probiotic capsule, yogurt, fermented dairy, kimchi, or another fermented food containing this species or close relatives can carry the number up, then let it fall back over days to weeks after you stop, depending on the strain.
• Stool consistency and transit time: looser, faster-moving stool dilutes and shifts measured bacterial abundance independent of what is actually growing in you.
• Lab method: absolute counts vary with storage, DNA extraction, and the DNA target the assay uses. The Lactobacillus casei group is genetically close enough that assays differ in how cleanly they separate members, and product labels sometimes name a different species than the one inside.
• Cross-lab disagreement: direct-to-consumer microbiome services show major discrepancies on identical samples, so numbers from two companies are not interchangeable.

Why One Reading Is Not Enough

Given that variability, a single stool value is close to uninterpretable on its own. What has actual meaning is a before-and-after pair around a deliberate change.

The practical protocol: test before starting a probiotic, then retest while you are still taking it, not after. Because the signal can fade within days of your last dose, a sample collected a week or two after you stop can look like you never took anything. If you are tracking a longer-term diet or symptom change, use the same lab and repeat after the change has been stable long enough to test. Annual retesting only makes sense as part of a broader stool panel, not as a rule for this species alone.

High-frequency sampling research in infants makes the timing problem clear: weekly collection can miss transient probiotic signals that daily collection catches. Timing your sample relative to your dosing matters more than the absolute number you get back.

What to Do With an Unexpected Result

If the number is undetectable while you are taking a product labeled to contain this species, the first question is whether the product is delivering live organisms at all. The second is whether the assay's DNA target matches the strain you are taking. Retest during active dosing before concluding the supplement is inert.

If you are chasing gut symptoms rather than supplement verification, this single species is the wrong lens. Order it inside a broader stool panel so you can see the pattern. Short-chain fatty acids are small acids gut bacteria make when they break down fiber. Calprotectin marks gut inflammation, pancreatic elastase reflects digestive enzyme output, and Collinsella helped predict probiotic response in irritable bowel syndrome studies. A high calprotectin with ongoing symptoms points toward inflammatory bowel disease and warrants a gastroenterologist and likely a scope, regardless of what this species is doing.

And if you have blood in the stool, unintended weight loss, fever, or night-time diarrhea that wakes you, skip the microbiome interpretation and get evaluated. Those symptoms need a clinician, not a probiotic.